Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

MLA

Anthony Turkiewicz, et al. “Efficacy and Safety of Intravenous Golimumab plus Methotrexate in Patients with Rheumatoid Arthritis Aged < 65 Years and Those ≥ 65 Years of Age.” Arthritis Research & Therapy, vol. 21, no. 1, Aug. 2019, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s13075-019-1968-x.

APA

Anthony Turkiewicz, Elizabeth C. Hsia, Raphael J. DeHoratius, Stephen Xu, John Tesser, & S. Kafka. (2019). Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age. Arthritis Research & Therapy, 21(1), 1–9. https://doi.org/10.1186/s13075-019-1968-x

Chicago

Anthony Turkiewicz, Elizabeth C. Hsia, Raphael J. DeHoratius, Stephen Xu, John Tesser, and S. Kafka. 2019. “Efficacy and Safety of Intravenous Golimumab plus Methotrexate in Patients with Rheumatoid Arthritis Aged < 65 Years and Those ≥ 65 Years of Age.” Arthritis Research & Therapy 21 (1): 1–9. doi:10.1186/s13075-019-1968-x.